Summary
Global Markets Direct’s, ‘Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2016’, provides an overview of the Chronic Kidney Disease (Chronic Renal Failure) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure)
- The report reviews pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Chronic Kidney Disease (Chronic Renal Failure) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Kidney Disease (Chronic Renal Failure) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Chronic Renal Failure
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Acceleron Pharma, Inc.
Angion Biomedica Corp.
Astellas Pharma Inc.
Bayer AG
Bio-inRen
BioAegis Therapeutics, Inc.
Boryung Pharmaceutical Co., Ltd.
Complexa, Inc.
Evotec AG
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Intercept Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc.
Lupin Limited
Nippon Zoki Pharmaceutical Co., Ltd.
OPKO Health, Inc.
Otsuka Holdings Co., Ltd.
Prismic Pharmaceuticals, Inc.
Prolong Pharmaceuticals, LLC
ProMetic Life Sciences Inc.
Reata Pharmaceuticals, Inc.
Red Glead Discovery AB
RegenMedTX, LLC
Resverlogix Corp.
Sphaera Pharma Pvt. Ltd.
Stelic Institute & Co., Inc.
Thrasos Therapeutics Inc.
Toray Industries, Inc.
VBS Pharmaceuticals
Vicore Pharma AB
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Kidney Disease (Chronic Renal Failure) Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) – Overview 9
Pipeline Products for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis 10
Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics under Development by Companies 11
Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics under Investigation by Universities/Institutes 13
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Chronic Kidney Disease (Chronic Renal Failure) – Products under Development by Companies 18
Chronic Kidney Disease (Chronic Renal Failure) – Products under Investigation by Universities/Institutes 21
Chronic Kidney Disease (Chronic Renal Failure) – Companies Involved in Therapeutics Development 22
Acceleron Pharma, Inc. 22
Angion Biomedica Corp. 23
Astellas Pharma Inc. 24
Bayer AG 25
Bio-inRen 26
BioAegis Therapeutics, Inc. 27
Boryung Pharmaceutical Co., Ltd. 28
Complexa, Inc. 29
Evotec AG 30
F. Hoffmann-La Roche Ltd. 31
Gilead Sciences, Inc. 32
Intercept Pharmaceuticals, Inc. 33
Ionis Pharmaceuticals, Inc. 34
Lupin Limited 35
Nippon Zoki Pharmaceutical Co., Ltd. 36
OPKO Health, Inc. 37
Otsuka Holdings Co., Ltd. 38
Prismic Pharmaceuticals, Inc. 39
Prolong Pharmaceuticals, LLC 40
ProMetic Life Sciences Inc. 41
Reata Pharmaceuticals, Inc. 42
Red Glead Discovery AB 43
RegenMedTX, LLC 44
Resverlogix Corp. 45
Sphaera Pharma Pvt. Ltd. 46
Stelic Institute & Co., Inc. 47
Thrasos Therapeutics Inc. 48
Toray Industries, Inc. 49
VBS Pharmaceuticals 50
Vicore Pharma AB 51
Chronic Kidney Disease (Chronic Renal Failure) – Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Combination Products 53
Assessment by Target 54
Assessment by Mechanism of Action 57
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
(palmidrol + silibinin) - Drug Profile 64
ambrisentan - Drug Profile 65
ANG-3070 - Drug Profile 67
ANG-3281 - Drug Profile 68
ANG-3586 - Drug Profile 69
ANG-4011 - Drug Profile 70
apabetalone - Drug Profile 71
AS-2444697 - Drug Profile 74
ASP-6858 - Drug Profile 75
bardoxolone methyl - Drug Profile 76
BR-05001 - Drug Profile 79
BRN-1889 - Drug Profile 80
C-21 - Drug Profile 81
calcium succinate - Drug Profile 83
CAR Peptide - Drug Profile 84
cardiotoxin - Drug Profile 85
Cell Therapy for Chronic Kidney Disease and Type-2 diabetes - Drug Profile 86
CXA-10 - Drug Profile 87
Drug for Kidney Diseases - Drug Profile 88
Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology - Drug Profile 89
finerenone - Drug Profile 90
INT-767 - Drug Profile 91
IONIS-FXIRx - Drug Profile 93
KBP-5074 - Drug Profile 94
NZ-419 - Drug Profile 95
obinutuzumab - Drug Profile 96
PBI-4050 - Drug Profile 100
PBI-4419 - Drug Profile 102
Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile 103
Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 105
rivaroxaban - Drug Profile 106
Sanguinate - Drug Profile 112
Small Molecule to Agonize CaSR for Chronic Kidney Disease and Primary Hyperparathyroidism - Drug Profile 114
Small Molecule to Inhibit Sodium-Phosphate Cotransporter 2b for CKD and Hypertension - Drug Profile 115
Small Molecules for Chronic Kidney Disease - Drug Profile 116
Small Molecules for Chronic Kidney Disease - Drug Profile 117
Small Molecules to Inhibit Soluble Epoxide Hydrolase for Chronic Kidney Disease - Drug Profile 118
Small Molecules to Inhibit SphK2 for Oncology, Kideny Disease, Autoimmune Disorders, Fibrosis and Neurodegenerative Diseases - Drug Profile 119
sotatercept - Drug Profile 120
SP-20103 - Drug Profile 122
SPR-494 - Drug Profile 123
STNM-310 - Drug Profile 124
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 125
Synthetic Peptides for Chronic Kidney Disease - Drug Profile 126
TNT-009 - Drug Profile 127
tolvaptan - Drug Profile 128
torsemide ER - Drug Profile 131
TRC-101 - Drug Profile 132
Vida-5 - Drug Profile 133
Chronic Kidney Disease (Chronic Renal Failure) – Recent Pipeline Updates 134
Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects 176
Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products 178
Chronic Kidney Disease (Chronic Renal Failure) – Product Development Milestones 180
Featured News & Press Releases 180
Appendix 187
Methodology 187
Coverage 187
Secondary Research 187
Primary Research 187
Expert Panel Validation 187
Contact Us 187
Disclaimer 188
List of Tables
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2016 13
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Number of Products under Development by Companies, H1 2016 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2016 17
Comparative Analysis by Late Stage Development, H1 2016 18
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Development, H1 2016 20
Comparative Analysis by Unknown Stage Development, H1 2016 21
Products under Development by Companies, H1 2016 22
Products under Development by Companies, H1 2016 (Contd..1) 23
Products under Development by Companies, H1 2016 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2016 25
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Acceleron Pharma, Inc., H1 2016 26
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Angion Biomedica Corp., H1 2016 27
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Astellas Pharma Inc., H1 2016 28
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bayer AG, H1 2016 29
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Bio-inRen, H1 2016 30
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by BioAegis Therapeutics, Inc., H1 2016 31
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 32
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Complexa, Inc., H1 2016 33
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Evotec AG, H1 2016 34
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 35
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Gilead Sciences, Inc., H1 2016 36
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Intercept Pharmaceuticals, Inc., H1 2016 37
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Ionis Pharmaceuticals, Inc., H1 2016 38
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Lupin Limited, H1 2016 39
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Nippon Zoki Pharmaceutical Co., Ltd., H1 2016 40
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by OPKO Health, Inc., H1 2016 41
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Otsuka Holdings Co., Ltd., H1 2016 42
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Prismic Pharmaceuticals, Inc., H1 2016 43
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Prolong Pharmaceuticals, LLC, H1 2016 44
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by ProMetic Life Sciences Inc., H1 2016 45
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Reata Pharmaceuticals, Inc., H1 2016 46
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Red Glead Discovery AB, H1 2016 47
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by RegenMedTX, LLC, H1 2016 48
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Resverlogix Corp., H1 2016 49
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 50
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Stelic Institute & Co., Inc., H1 2016 51
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Thrasos Therapeutics Inc., H1 2016 52
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Toray Industries, Inc., H1 2016 53
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by VBS Pharmaceuticals, H1 2016 54
Chronic Kidney Disease (Chronic Renal Failure) – Pipeline by Vicore Pharma AB, H1 2016 55
Assessment by Monotherapy Products, H1 2016 56
Assessment by Combination Products, H1 2016 57
Number of Products by Stage and Target, H1 2016 59
Number of Products by Stage and Mechanism of Action, H1 2016 62
Number of Products by Stage and Route of Administration, H1 2016 65
Number of Products by Stage and Molecule Type, H1 2016 67
Chronic Kidney Disease (Chronic Renal Failure) Therapeutics – Recent Pipeline Updates, H1 2016 138
Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects, H1 2016 180
Chronic Kidney Disease (Chronic Renal Failure) – Dormant Projects (Contd..1), H1 2016 181
Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products, H1 2016 182
Chronic Kidney Disease (Chronic Renal Failure) – Discontinued Products (Contd..1), H1 2016 183
List of Figures
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2016 13
Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure) – Comparative Analysis, H1 2016 14
Number of Products under Development by Companies, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 19
Comparative Analysis by Early Stage Products, H1 2016 20
Assessment by Monotherapy Products, H1 2016 56
Number of Products by Top 10 Targets, H1 2016 58
Number of Products by Stage and Top 10 Targets, H1 2016 58
Number of Products by Top 10 Mechanism of Actions, H1 2016 61
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 61
Number of Products by Routes of Administration, H1 2016 64
Number of Products by Stage and Routes of Administration, H1 2016 64
Number of Products by Molecule Types, H1 2016 66
Number of Products by Stage and Molecule Types, H1 2016 66
